5 Dumbest Things on...
Health Care: Health Services
Trius Therapeutics Inc. (TSRX: NASDAQ)
$7.95 0.05 | 0.63%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -53.93M | -18.25M | -23.86M | -22.68M |
| Operating Gains/Losses | 0.00 | -1.56M | -467.00K | 254.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -1.43M | -2.44M | -1.14M | -31.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.99M | 1.63M | 1.54M | -544.00K |
| (Decrease) Increase In Other Current Liabilities | 807.00K | 5.33M | 827.00K | 9.00K |
| (Increase) Decrease In Other Working Capital | -161.00K | -11.00K | -151.00K | -70.00K |
| Other Non-Cash Items | -212.00K | 2.82M | 4.94M | 1.46M |
| Net Cash From Continuing Operations | -49.50M | -13.24M | -18.72M | -20.67M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -49.50M | -13.24M | -18.72M | -20.67M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 77.04M | 47.03M | 0.00 | 10.50M |
| Purchases of Property, Plant & Equipment | -613.00K | -833.00K | -593.00K | -160.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -79.70M | -64.59M | -30.96M | -3.56M |
| Other Cash from Investing Activities | -1.00K | -150.00K | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -3.27M | -18.54M | -31.55M | 6.78M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 19.16M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 57.75M | 28.65M | 48.51M | 23.00K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -70.00K | -169.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | -1.00K | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | -1.92M | -1.38M |
| Net Cash From Financing Activities | 57.75M | 28.65M | 46.52M | 17.64M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 4.99M | -3.13M | -3.74M | 3.75M |
Portfolios with TSRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserAshley
- ContributorUnder-$10 Setting Up To Tra...
- ContributorStocks Under-$10 Moving Hig...
Latest TSRX Headlines from TheStreet
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tap 05.22.13 | 07:05 am
- Trius Announces Notice Of Allowance Of U.S. Patent Application Related To Tedizolid Phosphate Combination With Daptomycin 05.13.13 | 08:05 am
- Trius Therapeutics Reports First Quarter 2013 Financial Results 05.07.13 | 04:05 pm
- Cramer's Top Stock Picks: BRK.B FB TSRX 05.04.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan (Correct) 05.03.13 | 07:05 pm
- Trius Therapeutics Presents Clinical Data On Experimental Antibiotic Tedizolid At ECCMID Meeting 04.29.13 | 08:04 am
- Trius Therapeutics To Present Experimental Antibiotic Study Results At ECCMID Meeting 04.23.13 | 08:04 am
- Trius Appoints Seth Fischer To Its Board Of Directors 04.03.13 | 04:04 pm
- Trius To Present At Future Leaders Conference 04.02.13 | 04:04 pm
- Trius Announces Positive Results From ESTABLISH 2 Study Of Tedizolid In Severe Skin Infections 03.25.13 | 07:03 am
Press Releases for TSRX
- Trius Announces Issuance Of Key U.S. Patent For Torezolid Phosphate - PR Newswire 10.25.10 | 04:10 pm
- Trius To Present At San Diego Biotechnology Network Event - PR Newswire 10.22.10 | 04:10 pm
- Trius To Present At 7th Anti-Infectives Partnering And Deal-Making Summit - PR Newswire 10.06.10 | 04:10 pm
- Trius To Participate In Antibiotics Panel Discussion At Citi's 5th Annual Biotech Day - PR Newswire 10.04.10 | 08:10 am
- Trius Reports New Findings On Mechanisms Of Antibiotic Resistance In MRSA - PR Newswire 09.13.10 | 04:09 pm
- Trius To Present At The Stifel Nicolaus Healthcare Conference - PR Newswire 09.13.10 | 08:09 am
- Trius Therapeutics To Present Data From Drug Development Programs At ICAAC - PR Newswire 09.07.10 | 04:09 pm
- Trius Therapeutics Initiates Phase 3 Program Of Oral Torezolid Phosphate For The Treatment Of ABSSSI - PR Newswire 08.30.10 | 08:08 am
Partner Headlines for TSRX
- Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13) - Seeking Alpha 05.05.13 | 06:05 am
- Oppenheimer Reiterates Outperform Rating, $12 PT on Trius Therapeutics on 4Q12 EPS - Benzinga 03.13.13 | 01:03 pm
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Who Is Paying Attention To MRSA? - Seeking Alpha 10.23.12 | 09:10 am
- The Company You Keep Speaks Volumes: Novabay And Trius - Seeking Alpha 10.09.12 | 09:10 am
- Big Pharma Abandons Antibiotics: An Opening For Small Biotech - Seeking Alpha 05.13.12 | 09:05 am
- Trius Therapeutics: Outstanding Potential, Discount Price - Seeking Alpha 01.26.12 | 09:01 am
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
